Fierce Pharma Asia—Astellas CEO’s 5-year plan; Takeda’s psoriasis win; RA’s China bridge program FiercePharma 3d
‘Not simply saving cost’: Inside Astellas CEO’s 5-year strategy to counter Xtandi’s patent cliff FiercePharma 3d
Roche and Nestlé fear talent crunch as Switzerland puts population cap to the polls Fortune 3d Switzerland Roche Swiss Economy
Why Big Pharma Should Pay Attention To GLP-1 Drug Use Insights From Brazil Scrip Pharma Intelligence 3d Brazil South America Latin America
